Viewpoint Molecular Targeting™ Receives FDA Clearance of Investigational New Drug Application for Phase 1 Imaging Study for VMT-a-NET for Neuroendocrine Tumors

– VMT-a-NET Phase 1 imaging study to be followed by Phase 1/2a therapy study for the treatment of neuroendocrine tumors being conducted at the University of Iowa – – Preclinical efficacy results demonstrated VMT-a-NET to significantly inhibit tumor growth and improve survival compared to untreated controls – – VMT-a-NET imaging study provisional results expected in Q4 2021 –

Viewpoint Molecular Targeting® Partners with Industry Leader Pepscan to Accelerate Peptide Discovery Program

Coralville, IA, July 7, 2021 – Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced it has entered into a collaborative partnership with Netherlands-based Pepscan Therapeutics B.V. (“Pepscan”), the all-in-one peptide service provider with proprietary peptide constraining technologies.

EDC Client Case Study: Viewpoint Molecular Targeting

EDC is proud to support a variety of high-impact Iowa businesses at all stages. One of those, Viewpoint Molecular Targeting, is a biotech startup based in Coralville that has developed cancer diagnostics and treatment products that are safer for patients. We hope that you enjoy reading about this exciting Iowa business that is making an impact on cancer diagnosis and treatment. 

Ground-Breaking Treatment for Hard-to-Treat Cancers

KemPharm Announces FDA Approval of AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), A New Once-Daily Treatment for ADHD

KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for (NDA) AZSTARYS™ (formerly referred to as KP415), a once-daily product for the treatment of attention deficit hyperactivity disorder (ADHD) in patients age six years and older. AZSTARYS consists of serdexmethylphenidate (SDX), KemPharm’s prodrug of d-methylphenidate (d-MPH), co-formulated with immediate-release d-MPH.

VIDA, UnityPoint Health join forces to modernize lung and respiratory care with agreement to implement AI-powered lung intelligence solutions across the UnityPoint Health system

Partnership raises the bar on standards of care for patients by advancing the detection and treatment of complex lung disease, including COVID-19

Pages

Subscribe to News & Announcements